

Pembrolizumab KEYNOTE-048

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



No QoL benefit



**Serious and disabling adverse effects**



**Other adjustments**



Pembrolizumab KEYNOTE-048

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Head and neck cancer

Therapeutic Indication: In combination with platinum and 5-fluorouracil (5-FU) chemotherapy is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a CPS  $\geq$  1

Experimental Arm: Pembrolizumab + Cisplatin or carboplatin/5-FU

Control Arm: Cisplatin or carboplatin/5-FU/cetuximab



